Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIC-13: Hyperpolarized 13C-pyruvate MRI Feasibility
NCT06645691Phase 2Recruiting
- Sponsor
- National Heart Centre Singapore
- Start
- Oct 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hyperpolarized 13C-pyruvate in cardiovascular diseases (CVD) and metabolic syndrome, sponsored by National Heart Centre Singapore. Primary endpoint: Feasibility and reproducibility of Imaging Technique. Started Oct 2024; status: recruiting.
02
Drugs
hyperpolarized 13C-pyruvate
03
Conditions
cardiovascular diseases (CVD)metabolic syndrome
Beyond the preview
Go deeper on NCT06645691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645691.